CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2015年 / 5卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-RW2015-001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [1] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [4] CDK4/6 for ER+
    Mayer, I. A.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
    Roya Behrouzi
    Anne C. Armstrong
    Sacha J. Howell
    Breast Cancer Research and Treatment, 2023, 202 : 83 - 95
  • [6] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer andtriple negative breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [8] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [9] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [10] Palbociclib Ups PFS in HER2-/ER+ Breast Cancer
    不详
    CANCER DISCOVERY, 2014, 4 (06) : 624 - 625
12345